Atrium Therapeutics, Inc.

NASDAQ:RNA

Biotechnology

Healthcare
$6.64 +1.28%

+$0.16 today

Market cap
$143.23M
Beta
0.42
P/E (TTM)
-3.3
EPS (TTM)
-$3.78
52W Low $11.40High $16.77

Volume 0.22M

Average 0.35M

RNA EBITDA Margin

EBITDA as a percentage of revenue.

Atrium Therapeutics, Inc.NASDAQ: RNA

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin at -83.9%

EBITDA Margin was -83.9% in Q1 FY2026.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 3 analysts of -134.0% for the fiscal year ending Dec 2026, up from -410.9% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-83.9%+5493.8 pp QoQ
Last fiscal yearDec 2025
-410.9%— YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year—+276.9 pp—
3 years—-3131.9 pp—
5 years+122.1 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-410.9%
Year-over-year change
—
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How RNA compares with its peers on the latest reported figures

No competitor EBITDA Margin figures are available to compare.

Atrium Therapeutics, Inc.

NASDAQ:RNA

Intrinsic Alpha fair value

Locked

Current Price

$6.64

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.